Welcome to our dedicated page for Phibro Animal SEC filings (Ticker: PAHC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking how antibiotic regulations, feed ingredient prices, and vaccination uptake affect Phibro Animal Health Corporation can mean sifting through hundreds of pages of SEC disclosures. Every 10-K details global livestock trends, and each 8-K might flag new FDA approvals or supply-chain risks. Finding when executives exercise options or which segment drives growth is essential, yet manual searches consume hours. Stock Titan’s AI turns these dense documents into clear intelligence the moment they are filed.
Our engine ingests every Phibro Animal Health quarterly earnings report 10-Q filing, compares it with prior periods, and highlights changes across Animal Health, Mineral Nutrition, and Performance Products. Need to monitor Phibro Animal Health insider trading Form 4 transactions? You’ll get real-time alerts plus plain-English context. The platform clusters documents so you know exactly where to look:
- Phibro Animal Health annual report 10-K simplified for long-term trend review
- Phibro Animal Health Form 4 insider transactions real-time notifications
- Phibro Animal Health executive stock transactions Form 4 with AI commentary
- Phibro Animal Health proxy statement executive compensation distilled
- Phibro Animal Health 8-K material events explained within minutes
Ask, “How are Phibro Animal Health SEC filings explained simply?” or “Where can I find a Phibro Animal Health earnings report filing analysis?”—Stock Titan already has the answer. Our models translate accounting notes, segment metrics, and litigation risks into concise narratives, understanding Phibro Animal Health SEC documents with AI so you don’t have to. From insider alerts to side-by-side ratio comparisons, you’ll gain the clarity needed to act decisively.
Phibro Animal Health Corporation is planning a leadership transition. Jack C. Bendheim, currently Chairman, Chief Executive Officer and President, will resign from the CEO and President roles effective July 1, 2026, and move into a new managerial position as Executive Chairman. He will remain Chairman of the Board and continue to provide strategic oversight and work with the executive team.
On that same date, Daniel (Dani) Bendheim, age 53 and currently Executive Vice President, Corporate Strategy, will become Chief Executive Officer and President. He has been with the company since 1997, has held multiple senior roles including President of Performance Products, and has served on the Board since November 2013. Dani Bendheim is Jack Bendheim’s son and part of the Bendheim family investment vehicle BFI Co., LLC. Both Jack and Dani Bendheim are expected to enter into new or amended employment agreements before the transition becomes effective.
Phibro Animal Health Corp. insider Jack Bendheim, who serves as President, CEO, director and a 10% owner, reported sales of Class A common stock on
The transactions, made by affiliated entity BFI Co., LLC under a Rule 10b5-1 trading plan adopted on
Phibro Animal Health (PAHC) President and CEO Jack Bendheim, who is also a director and 10% owner, reported sales of Class A common stock on 11/20/2025. Through BFI Co., LLC, he sold 3,459 shares at a weighted average price of $41.752 and an additional 61 shares at $42.32, all under a pre-arranged Rule 10b5-1 trading plan adopted on May 30, 2025.
Following these transactions, 46,221 shares were reported as indirectly owned before the second sale and 46,160 shares as indirectly owned afterward through BFI, with another 16,840 shares held directly by Bendheim. The filing notes that the reported prices reflect weighted averages across multiple trades between $41.29 and $42.25, and Bendheim disclaims beneficial ownership of BFI-held shares beyond his economic interest.
Phibro Animal Health (PAHC) president and CEO Jack Bendheim, a director and 10% owner, reported insider transactions involving the company’s Class A and Class B common stock. On 11/14/2025, 55,000 shares of Class B common stock were converted into 55,000 shares of Class A common stock at an exercise price of $0 under a derivative security.
Following the conversion, indirect holdings sold 5,280 Class A shares on 11/17/2025 at a weighted average price of $44.5557 and 5,260 shares plus 20 shares on 11/18/2025 at weighted average prices of $43.8196 and $44.28, respectively, under a Rule 10b5-1 trading plan adopted by BFI Co., LLC on May 30, 2025. After these transactions, 49,680 Class A shares were held indirectly through BFI and 16,840 Class A shares were held directly, with 19,991,034 Class B derivative securities indirectly owned.
Phibro Animal Health (PAHC) insider activity: A Form 4 reports transactions by Jack Bendheim and BFI Co., LLC. On 11/11/2025, 15,000 shares of Class B Common Stock were converted into Class A Common Stock at $0. On 11/12/2025, 21,536 Class A shares were sold at a weighted average price of $45.2255. On 11/13/2025, additional sales included 7,147 shares at $44.3689 and 1,654 shares at $44.929. These sales were effected under a Rule 10b5-1 trading plan adopted on May 30, 2025. Following the reported transactions, Class A shares beneficially owned were 5,240 indirect (via BFI) and 16,840 direct.
Phibro Animal Health (PAHC): Reporting persons Jack Bendheim and BFI Co., LLC disclosed open‑market sales of Class A common stock totaling 41,823 shares on 11/07/2025 and 11/10/2025, executed at average prices ranging from $42.8554 to $46.3558 under a Rule 10b5‑1 trading plan adopted on May 30, 2025.
Following these transactions, 20,577 shares are held indirectly via BFI and 16,840 shares are held directly by Mr. Bendheim. Bendheim is a Director, President and CEO, and 10% owner.
Phibro Animal Health (PAHC): Jack Bendheim and BFI Co., LLC reported insider transactions on Form 4. On 11/04/2025, BFI converted 25,000 shares of Class B Common Stock into Class A Common Stock (one-for-one, no expiration). On 11/04/2025 and 11/05/2025, BFI sold a total of 7,040 Class A shares under a Rule 10b5-1 trading plan adopted on May 30, 2025, at weighted average prices ranging from $40.9805 to $43.6205.
Following these transactions, 62,400 Class A shares were indirectly beneficially owned and 16,840 Class A shares were directly beneficially owned. Bendheim is a Director, President and CEO, and 10% Owner, and may be deemed to share voting and investment power over BFI’s holdings.
Phibro Animal Health (PAHC) furnished a press release announcing operating results for the fiscal quarter ended September 30, 2025 and financial guidance for the fiscal year ending June 30, 2026 as Exhibit 99.1.
At the November 4, 2025 annual meeting, holders representing 97.3% of voting power were present, including 14,543,375 Class A shares and 20,166,034 Class B shares as of the September 12, 2025 record date. All three director nominees were elected. The advisory vote on executive compensation passed with 213,516,403 votes for, 1,184,154 against, and 20,495 abstentions, with 1,482,663 broker non-votes. Stockholders advised a three-year frequency for future say‑on‑pay votes, with 202,618,936 votes for three years. The selection of PwC as independent auditor for fiscal 2026 was ratified with 214,368,092 votes for, 1,824,908 against, and 10,713 abstentions; there were no broker non‑votes.
Phibro Animal Health (PAHC) reported strong quarterly growth with net sales of $363.9 million for the three months ended September 30, 2025, up 40% year over year. Operating income rose to $51.3 million from $17.7 million, and net income increased to $26.5 million, or $0.65 per diluted share, versus $0.17 a year ago. Gross profit reached $119.8 million.
Animal Health led results with $283.5 million in sales, including medicated feed additives and other products at $195.2 million, nutritional specialties at $48.2 million, and vaccines at $40.1 million. The October 2024 acquisition of select Zoetis products contributed $80.5 million to the quarter’s revenue. By region, sales were $202.3 million in the U.S., $87.2 million in Latin America and Canada, $44.9 million in EMEA, and $29.4 million in Asia Pacific.
Balance sheet and cash flows: cash and cash equivalents were $72.8 million, inventories were $471.8 million, and total assets were $1.39 billion. Long‑term debt was $609.5 million, with $115.0 million drawn on the revolver and $192.1 million remaining available for borrowing and letters of credit. Net cash provided by operating activities was $9.3 million; capital expenditures were $13.8 million. Interest expense, net, was $12.1 million.
Phibro Animal Health Corporation declared a quarterly cash dividend of $0.12 per share on its Class A and Class B common stock. The dividend is payable on December 17, 2025 to stockholders of record at the close of business on November 26, 2025.
The company announced the dividend via a press release filed as Exhibit 99.1.
FAQ
What is the current stock price of Phibro Animal (PAHC)?
What is the market cap of Phibro Animal (PAHC)?
